HALO Stock Recent News

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.

Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance  Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, and non-GAAP Diluted EPS of $4.95 - $5.35, Representing YoY Growth of 21% - 30%1,2 Announces New $250 million Accelerated Share Repurchase Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance and raising full year 2025 and multi-year financial guidance. The Company also announced it has recently entered into a new $250 million accelerated share repurchase (ASR) program under its previously announced $750 million share repurchase program.

LDOS, AMZN, HALO & BMRN's impressive interest coverage ratios highlight that these companies can withstand financial hardships.

SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m.

Halozyme Therapeutics, Inc.'s subcu drug delivery business, driven by ENHANZE technology, shows strong revenue growth with significant collaborations, but faces potential challenges post-2030 due to expiring licensing agreements. The failed $2.1bn Evotec acquisition, while initially promising, may have been a blessing in disguise for HALO given Evotec's uncertain and loss-making business model. Recent approvals, including subcutaneous Opdivo (Qvantiq) and other products, e.g. Roche's Ocrevus, suggest a positive outlook for 2025, potentially boosting Halozyme's share price.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Wells Fargo has downgraded its rating for Halozyme Therapeutics (HALO, Financial), a U.S. biotechnology company, from "Overweight" to "Equal Weight," with a target price set at $62, indicating limited upside potential. This year, Halozyme's stock has surged by 50%, compared to the S&P 500's approximately 21% rise.

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.